1.Message from the Editor-in-Chief: Theranostic Imaging in 2018
Nuclear Medicine and Molecular Imaging 2018;52(2):87-88
No abstract available.
Theranostic Nanomedicine
2.Contribution of Radionuclide Theranostics for Managing Intractable Malignancies
Nuclear Medicine and Molecular Imaging 2018;52(3):168-169
No abstract available.
Theranostic Nanomedicine
3.Nuclear Theranostics in Asia: In vivo Companion Diagnostics
Nuclear Medicine and Molecular Imaging 2019;53(1):1-6
No abstract available.
Asia
;
Friends
;
Humans
;
Theranostic Nanomedicine
4.Nuclear Theranostics in Indonesia: Past, Present, and Future
Nuclear Medicine and Molecular Imaging 2019;53(1):33-34
Nuclear medicine in Indonesia has a quite long history since the late 1960s. There are some problems and obstacles that have to be solved and overcome in order to develop nuclear medicine services, spread the services to reach every target area, and implement new novel therapeutic nuclear medicine as well. The right strategy and strong effort should be performed for a successful result. Theranostics nuclear medicine will play a more prominent role in the management of cancer patients.
Humans
;
Indonesia
;
Nuclear Medicine
;
Theranostic Nanomedicine
5.Review: optically-triggered phase-transition droplets for photoacoustic imaging.
Qiyang CHEN ; Jaesok YU ; Kang KIM
Biomedical Engineering Letters 2018;8(2):223-229
Optically-triggered phase-transition droplets have been introduced as a promising contrast agent for photoacoustic and ultrasound imaging that not only provide significantly enhanced contrast but also have potential as photoacoustic theranostic molecular probes incorporated with targeting molecules and therapeutics. For further understanding the dynamics of optical droplet vaporization process, an innovative, methodical analysis by concurrent acoustical and ultrafast optical recordings, comparing with a theoretical model has been employed. In addition, the repeatability of the droplet vaporization-recondensation process, which enables continuous photoacoustic imaging has been studied through the same approach. Further understanding the underlying physics of the optical droplet vaporization and associated dynamics may guide the optimal design of the droplets. Some innovative approaches in preclinical studies have been recently demonstrated, including sono-photoacoustic imaging, dual-modality of photoacoustic and ultrasound imaging, and super-resolution photoacoustic imaging. In this review, current development of optically triggered phase-transition droplets and understanding on the vaporization dynamics, their applications are introduced and future directions are discussed.
Methods
;
Models, Theoretical
;
Molecular Probes
;
Theranostic Nanomedicine
;
Ultrasonography
;
Volatilization
6.Nuclear Medicine Theranostics: Perspective from Pakistan
Humayun BASHIR ; M Numair YOUNIS ; M Rehan GUL
Nuclear Medicine and Molecular Imaging 2019;53(1):38-41
Nuclear medicine has been offering diagnostic and therapeutic solution since the introduction of radioactive iodine for thyroid diseases since decades. However, the concept of theranostics has given a new found impetus to the use of pairs of radiopharmaceuticals for diagnosis and treatment. Presented here is a perspective on theranostics from Pakistan.
Diagnosis
;
Iodine
;
Nuclear Medicine
;
Pakistan
;
Radiopharmaceuticals
;
Theranostic Nanomedicine
;
Thyroid Diseases
7.Perspectives for Concepts of Individualized Radionuclide Therapy, Molecular Radiotherapy, and Theranostic Approaches
Nuclear Medicine and Molecular Imaging 2019;53(3):167-171
Radionuclide therapy (RNT) stands on the delivery of radiation to tumors or non-tumor target organs using radiopharmaceuticals that are designed to have specific affinity to targets. RNT is recently called molecular radiotherapy (MRT) by some advocators in order to emphasize its characteristics as radiotherapy and the relevance of dosimetry-guided optimization of treatment. Moreover, RNT requires relevant radiation protection standards because it employs unsealed radionuclides and gives therapeutic radiation doses in humans. On the basis of these radiation protection standards, the development and use of radiopharmaceuticals for combined application through diagnostics and therapeutics lead to theranostic approaches that will enhance the efficacy and safety of treatment by implementing dosimetry-based individualization.
Humans
;
Radiation Protection
;
Radioisotopes
;
Radiopharmaceuticals
;
Radiotherapy
;
Theranostic Nanomedicine
8.Radio-graphene in Theranostic Perspectives
Nuclear Medicine and Molecular Imaging 2017;51(1):17-21
Owing to its unique physicochemical properties such as high surface area, notable biocompatibility, robust mechanical strength, high thermal conductivity, and ease of functionalization, 2D-layered graphene has received tremendous attention as a futuristic nanomaterial and its-associated research has been rapidly evolving in a variety of fields.With the remarkable advances of graphene especially in the biomedical realm, in vivo evaluation techniques to examine in vivo behavior of graphene are largely demanded under the hope of clinical translation. Many different types of drugs such as the antisense oligomer and chemotherapeutics require optimal delivery conveyor and graphene is now recognized as a suitable candidate due to its simple and high drug loading property. Termed as ‘ radio-graphene’, radioisotope-labeled graphene approach was recently harnessed in the realm of biomedicine including cancer diagnosis and therapy, contributing to the acquisition of in vivo information for targeted drug delivery. In this review, we highlight current examples for bioapplication of radiolabeled graphene with brief perspectives on future strategies in its extensive bio- or clinical applications.
Diagnosis
;
Graphite
;
Hope
;
Nanostructures
;
Theranostic Nanomedicine
;
Thermal Conductivity
9.Analytical Performance of Bio-Rad D-100 on a Hemoglobin A1c Assay.
Changseung LIU ; Eunhye CHOI ; In Cheol BAE ; Sang Guk LEE ; Jeong Ho KIM
Laboratory Medicine Online 2017;7(2):59-65
BACKGROUND: Hemoglobin A1c (HbA1c) is considered a marker useful for the follow-up and diagnosis of diabetes and implies the importance of reliable assay methods that are traceable to a reference method. We evaluated analytical performance of a new high-performance liquid chromatography system for the HbA1c assay: D-100 from Bio-Rad Laboratories (USA). METHODS: We evaluated precision, linearity, and carry-over of D-100, according to the Clinical and Laboratory Standards Institute's guidelines. Comparative analysis of D-100 with Integra 800 (Roche Diagnostics, Germany) and Capillarys 3 (Sebia, France) was conducted. Additionally, we evaluated the throughput of the three instruments. RESULTS: Precision of low- and high-concentration controls in D-100 showed a CV of less than 1%. The linearity was excellent (R²=0.999) in the range of 3.51-18.7%, and carry-over was not observed. HbA1c results of D-100 (n=144) showed good correlation with those of Integra 800 (r=0.993) and Capillarys 3 (r=0.996). The % bias between D-100 and Integra 800 or Capillarys 3 was within the allowable range at all 3 medical decision levels (5.7%, 6.5%, and 10.0%). Elapsed time in the analysis of the first sample by D-100 was shorter than that of Integra 800 (2.4 vs. 11.1 minutes), but subsequent samples took more time (0.8 vs. 0.3 minutes per sample). CONCLUSIONS: D-100 showed reliable analytical performance with good precision and linearity, minimal carry-over, and acceptable comparative characteristics relative to other instruments. D-100 is expected to be useful for clinical measurements of HbA1c for diabetes diagnosis and theranostics.
Bias (Epidemiology)
;
Chromatography, Liquid
;
Diagnosis
;
Follow-Up Studies
;
Methods
;
Theranostic Nanomedicine
10.Activities for the Development of Targeted Radionuclide Therapy in Japan
Nuclear Medicine and Molecular Imaging 2019;53(1):35-37
Targeted radionuclide therapy (TRT) is unique because of its efficacy and its theranostic feature in the era of precision medicine. So far, introduction of new TRT has not been going well in Japan due to several reasons including strict regulations, shortage of facilities for TRT, and insufficient reimbursement for TRT in clinic. Japanese community had several strategies to develop TRT in these 10 years, including the establishment of the National Conference for Nuclear Medicine Theranostics in which physicians, scientists, patients, people supporting patients, and industrial people gather. To promote TRTwith supports from the government, the preparatory committee for the establishment of Japan Foundation of Medical Isotope Development (JAFMID) was launched. I would like to call TRT “Precision Nuclear Medicine.” When we can add genomic information here, we can put it to new stage of cancer therapy. It is time for us.
Asian Continental Ancestry Group
;
Humans
;
Japan
;
Nuclear Medicine
;
Precision Medicine
;
Social Control, Formal
;
Theranostic Nanomedicine